Cognition Therapeutics, Inc. (CGTX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Purchase, NY, United States. The current CEO is Lisa Ricciardi.
CGTX has IPO date of 2021-10-08, 25 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $71.77M.
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
